Regeneron Pharmaceuticals Inc. is urging the US Food and Drug Administration to use genomic information more broadly in evaluating the safety and efficacy of new drugs and wants the data to be included in product labeling.
The FDA convened a meeting on 7 November to gain stakeholder recommendations on how the Office of New Drugs could...